PDIA6 and renal cell carcinoma: These results provided a novel mechanism involved in PDIA6-mediated chemoresistance of renal cell carcinoma and highlighted the significance of PDIA6 inhibition as a potential therapeutic strategy for imatinib-resistant renal cell carcinoma.